Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor status to the choice of molecular therapy for patients with metastatic colorectal cancer. Whether the gene is wild-type or mutant determines sensitivity of the tumor to anti-epidermal growth factor or anti-vascular endothelial growth factor receptor therapy. Dr Macdonald also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.

You can listen to Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations? online on Radio and Podcast. Open the player on this page to stream the available audio.

Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations? is an episode from Oncology Times Broadcast News.

This episode is 00:03:39 long.

This episode was published on Sep 28, 2009.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Oncology Times Broadcast News when more episodes are available from the podcast feed.